Skip to main navigation
Skip to main content
Skip to Footer
English
Français
Canada
Répertoire du site Sandoz
Our Work
What We Do
Quality Generics
Biopharmaceuticals
Specialty Products
About Us
Who We Are
Corporate Responsibility
Doing Business Responsibly
Contact Us
Grants, Donations and Sponsorships
Products
Consumers
Patients
Healthcare Professionals
Patient Support Programs
News
Media Releases
Media Resource Center
Stay Up-To-Date
Careers
Available Positions
Diversity & Inclusion
Our Benefits
Sandoz-Connect Portal
Search
All News
Advanced Search
Basic Search
From Date:
To Date:
Show:
All
Media Releases
Filter By
2021
September
Media Release
/
Sep 01, 2021
Sandoz Canada launches PrSandoz® Lenalidomide, a generic equivalent to PrRevlimid®
Read More
June
Media Release
/
Jun 02, 2021
Biosimilars reimbursement update: Ontario adds Inclunox™ to its list of reimbursed drugs
Read More
May
Media Release
/
May 28, 2021
Accessa and Québec owner-pharmacists make their debut in the Patient Support Program sector with Sandoz Canada's Hyrimoz
Read More
Media Release
/
May 18, 2021
Sandoz Canada congratulates the Quebec government on implementing a shift towards biosimilars
Read More
Media Release
/
May 17, 2021
Sandoz Canada launches its 6th biosimilar with PrInclunox® and PrInclunox® HP
Read More
Media Release
/
May 12, 2021
A first in Canada: generic version of pirfenidone
Read More
April
Media Release
/
Apr 27, 2021
Novartis Q1 2021 Financial Results
Read More
Media Release
/
Apr 21, 2021
New biosimilar switch policy in New Brunswick improves patient access to safe and effective medicines
Read More
Media Release
/
Apr 13, 2021
Third consecutive recognition for Novartis in Canada as a Great Place to Work®
Read More
Media Release
/
Apr 09, 2021
Finalist at Les Mercuriades
Read More
Twitter
Tweet
Facebook
Share
Share
Twitter
Facebook
LinkedIn
Email
Jump to Comments
You are here
Home
›
